Core Insights - Apollomics Inc. has entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited to resolve litigation related to preferred share redemption claims before its merger with Maxpro Capital Acquisition Corporation in 2023 [1][2] Financial Summary - The settlement agreement requires Apollomics to pay a total of US$5 million in cash to TWVC, to be paid in installments over two years, along with approximately US$879,757.78 in legal expenses [2] - The original damages claimed by TWVC were approximately US$40 million, as disclosed in the Form 20-F filed in April 2025 [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that can be combined with other treatments to target specific molecular pathways and harness the immune system [3] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in a Phase 2 multicohort clinical trial [3]
Apollomics Announces Settlement of Cayman Litigation